Pacira BioSciences (NASDAQ:PCRX) Shares Up 4.7% on Analyst Upgrade

Pacira BioSciences, Inc. (NASDAQ:PCRX)’s share price traded up 4.7% during trading on Wednesday after Truist Financial raised their price target on the stock from $30.00 to $31.00. Truist Financial currently has a buy rating on the stock. Pacira BioSciences traded as high as $25.70 and last traded at $25.9250. Approximately 216,852 shares traded hands during trading, a decline of 67% from the average session volume of 662,612 shares. The stock had previously closed at $24.76.

Other equities research analysts also recently issued reports about the stock. Wall Street Zen raised shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 26th. Leerink Partners initiated coverage on Pacira BioSciences in a research note on Wednesday, September 9th. They issued a “market perform” rating and a $28.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $38.00 price target on shares of Pacira BioSciences in a report on Wednesday, July 1st. Zacks Research cut Pacira BioSciences from a “hold” rating to a “strong sell” rating in a research note on Monday. Finally, Oppenheimer initiated coverage on Pacira BioSciences in a research report on Wednesday, September 23rd. They set an “outperform” rating and a $32.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pacira BioSciences currently has an average rating of “Hold” and a consensus target price of $30.29.

Insiders Place Their Bets

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,040 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $23.23, for a total value of $70,619.20. Following the sale, the insider directly owned 216,384 shares in the company, valued at $5,026,600.32. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by corporate insiders.

Key Pacira BioSciences News

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Truist Financial raised its price target for Pacira BioSciences from $30 to $31 and initiated or reaffirmed a “buy” rating. The new target implies approximately 21% upside from recent trading levels, signaling confidence in Pacira’s valuation and growth outlook.
• Positive Sentiment: Pacira granted Molteni Farmaceutici exclusive rights to commercialize its EXPAREL postsurgical pain product in the European Union and United Kingdom. The partnership expands EXPAREL’s international reach and could create additional revenue opportunities without requiring Pacira to build its own commercial infrastructure in those markets. Pacira Announces Exclusive Agreement with Molteni Farmaceutici
• Positive Sentiment: The Molteni agreement is also supporting an “undervalued” investment narrative around PCRX, as investors assess the potential for broader EXPAREL adoption and international growth. Pacira BioSciences on Its Molteni Deal and the Undervalued Narrative
• Neutral Sentiment: A survey conducted with Caregiver Action Network found that families want clearer pain-management plans, earlier education, and more practical guidance on non-opioid options before surgery. The findings reinforce Pacira’s focus on non-opioid pain treatment, but the announcement does not include a specific financial outlook or new product approval. Pacira and Caregiver Action Network Survey
• Negative Sentiment: Zacks Research downgraded PCRX from “hold” to “strong sell,” creating a significant counterweight to Truist’s bullish view and potentially increasing volatility. Zacks Downgrades Pacira BioSciences

Institutional Trading of Pacira BioSciences

Several institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its stake in Pacira BioSciences by 5.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,060,597 shares of the company’s stock worth $46,572,000 after acquiring an additional 110,584 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Pacira BioSciences by 17.8% during the second quarter. Wellington Management Group LLP now owns 563,458 shares of the company’s stock worth $14,295,000 after purchasing an additional 85,075 shares in the last quarter. Gagnon Securities LLC lifted its holdings in shares of Pacira BioSciences by 11.5% in the 4th quarter. Gagnon Securities LLC now owns 501,211 shares of the company’s stock valued at $12,971,000 after purchasing an additional 51,494 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Pacira BioSciences in the 2nd quarter valued at about $7,532,000. Finally, Hillsdale Investment Management Inc. boosted its position in shares of Pacira BioSciences by 7.5% in the 1st quarter. Hillsdale Investment Management Inc. now owns 331,300 shares of the company’s stock valued at $7,487,000 after purchasing an additional 23,100 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Stock Up 2.9%

The stock has a market cap of $1.02 billion, a PE ratio of 72.78 and a beta of 0.25. The business has a 50 day moving average of $25.20 and a 200-day moving average of $24.39. The company has a current ratio of 5.04, a quick ratio of 3.94 and a debt-to-equity ratio of 0.54.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.08. The firm had revenue of $192.40 million during the quarter, compared to the consensus estimate of $191.06 million. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%.The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.74 EPS. Equities research analysts predict that Pacira BioSciences, Inc. will post 1.91 EPS for the current fiscal year.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.